Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06137144 · ClinicalTrials.gov registry record · Phase 1

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

A Phase 1 study of Lymphoma and Hodgkin Lymphoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
110
Enrollment target
20
Study locations

NCT06137144 is a Phase 1 study of Lymphoma and Hodgkin Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 110 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06137144, a Phase 1 study of Lymphoma and Hodgkin Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
110 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

Conditions Studied

Lymphoma Hodgkin Lymphoma Non-Hodgkin

Interventions

  • DRUG AZD3470

Study Locations (20)

Other

  • Research Site - Nedlands
  • Research Site - Créteil
  • Research Site - Lille
  • Research Site - Pierre-Bénite
  • Research Site - Villejuif
  • Research Site - Cologne
  • Research Site - Alessandria
  • Research Site - Bologna
  • Research Site - Milan
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - L'Hospitalet de Llobregat
  • Research Site - Madrid
  • Research Site - Manchester
  • Research Site - Oxford

Florida

  • Research Site - Miami

Georgia

  • Research Site - Atlanta

Massachusetts

  • Research Site - Boston

Pennsylvania

  • Research Site - Philadelphia

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2024-01-23
Est. Completion 2026-05-08
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06137144

The ClinicalTrials.gov registry entry for NCT06137144 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (77% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which AZD3470 is the first listed.

NCT06137144 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06137144 about?

NCT06137144 is a clinical study titled "AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.". This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

What is the current status of trial NCT06137144?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2024-01-23. Estimated completion is 2026-05-08.

What conditions does trial NCT06137144 study?

This clinical trial studies the following conditions: Lymphoma, Hodgkin Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT06137144?

The interventions under investigation include: AZD3470 (DRUG).

Who is sponsoring clinical trial NCT06137144?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06137144 being conducted?

This trial has 20 study locations across Florida, Georgia, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

Hodgkin Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.